The state of the IP union

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

The state of the IP union

Alice was the dominant topic in the AIPLA session "Addressing the Hot Topics of Today for Tomorrow's Business"

The first question that moderator Timothy Meigs of Beckton Dickinson asked the State of the IP Union Panel yesterday was: what keeps them and their clients up at night? The panel's subtitle was "Addressing the Hot Topics of Today for Tomorrow's Business," but the answer to this question was hardly a hot and fresh one: it's still Alice.

Philip Petti of USG Corporation commented: "It's sort of like we're sitting in the middle of the bus, and there's a crazy person at the wheel." Petti says he and his company feel the "reverberations" of the uncertainty brought on by Alice. From the statistics he's examined, "if our patents are tested, about 70% of them are going to fail," he said. "How do I advise my business people when I tell them we're going to put so much money into patenting that you can't even count on?"

As Microsoft's Micky Minhas sees it, Alice may be dissuading IP owners from other countries from patenting their products here, placing the US at a disadvantage. As China considers accepting patents for business methods, the US is heading "in the opposite direction," he said.

Pfizer's Adrian Looney praised Hatch-Waxman and the BPCIA for clearing the way for generics. But he also questioned whether, if the Alice decision had been handed down before the boom of generics, those pharmaceuticals that have saved many lives would even exist today. It was suggested that it is not just innovation in the biopharma space that Alice stands to inhibit. Qualcomm's Laurie Self said that funding for startups "depends on the VC community believing that you have a predictable right, an enforceable right." She added: "I really do worry that, through this constant diminishment of patent rights, you're making long-term research too risky an investment for startups."

Looney also pointed to the specificity of Hatch-Waxman litigation to one industry as a potential model for reform to 101 issues, which have been treated very inconsistently by the courts. Frustrating though the denial of cert for a number of recent 101 cases is, the panel conceded the Supreme Court has heard a number of IP cases and may still want to see the lower courts shake it out.

more from across site and SHARED ros bottom lb

More from across our site

News of Avanci hiring a senior vice president and the EPO teaming up with a French AI startup were also among the top talking points
Explosm, the independent Texas studio behind the hit webcomic Cyanide & Happiness, partnered with Temu’s IP protection team to combat counterfeiters infringing on its brand
The latest in a dispute over juicing machines, and a shakeup in judicial compositions were also among the top developments
Patent partner Robert Hollingshead explains why the firm remains committed to Japan despite several US firms exiting the Japanese and greater Asia market
Emma Green, partner at Bird & Bird, shares why the Iceland v Iceland dispute could prompt businesses and lawyers to think differently about brand enforcement
Attain IP, developed by two UK patent lawyers, will meet ‘forensic’ needs of patent attorneys by showing a verifiable reasoning chain, according to its co-founders
The High Court of Australia has allowed a fashion designer to retain her registered ‘Katie Perry’ trademark for clothing
Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Gift this article